HistoSonics, Inc

HistoSonics, Inc. is a medical device manufacturer specializing in histotripsy, a proprietary non-invasive ultrasound technology that mechanically destroys targeted tissue without surgery, heat, or incisions. Founded in 2009 by University of Michigan experts, the company has developed the Edison system—an FDA-approved, robotic, image-guided platform for the non-invasive mechanical destruction of liver tumors. The Edison system uses focused ultrasound to create a controlled bubble cloud that liquefies unwanted tissue in real-time at the sub-cellular level. With over 100 systems deployed globally and significant insurance coverage expansion (7 million BCBS Highmark members), HistoSonics is actively expanding clinical applications beyond liver oncology to kidneys and pancreas through ongoing HOPE4KIDNEY and GANNON clinical trials. The company serves interventional radiologists, surgical oncologists, hepatologists, and transplant surgeons, positioning histotripsy as a tissue-sparing alternative to traditional surgical and thermal ablation approaches for tumor treatment.